Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials

Pharmacological Research

Volumn 129, Issue , 2018, Pages 141-150

  Haghighatdoost, Fahimeh ^a,b   Hariri, Mitra ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NEYSHABUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Lipid profile; Meta analysis; Resveratrol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; TRIACYLGLYCEROL;

AGE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; DIETARY SUPPLEMENT; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; LIPID BLOOD LEVEL; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SEX; SYSTEMATIC REVIEW; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD;

HUMANS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESVERATROL;

EID: 85039980258     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.12.033     Document Type: Review

References (66)

1. Indolfi, C., De Rosa, S., Colombo, A., Bioresorbable vascular scaffolds – basic concepts and clinical outcome. Nat. Rev. Cardiol. 13 (2016), 719–729.
2. Shao, D., Wang, Y., Huang, Q., Shi, J., Yang, H., Pan, Z., et al. Cholesterol-lowering effects and mechanisms in view of bile acid pathway of resveratrol and resveratrol glucuronides. J. Pharm. Pharmacol., 2016.
3. Askari, G., Hajishafiee, M., Ghiasvand, R., Hariri, M., Darvishi, L., Ghassemi, S., et al. Quercetin and vitamin C supplementation: effects on lipid profile and muscle damage in male athletes. Int. J. Preventive Med. 4 (2013), 58–62.
4. Azimi, P., Ghiasvand, R., Feizi, A., Hariri, M., Abbasi, B., Effects of cinnamon, cardamom, saffron, and ginger consumption on markers of glycemic control, lipid profile, oxidative stress, and inflammation in type 2 diabetes patients. Rev. Diabetic Stud.: RDS 11 (2014), 258–266.
5. Feizollahzadeh, S., Ghiasvand, R., Rezaei, A., Khanahmad, H., Sadeghi, A., Hariri, M., Effect of probiotic soy milk on serum levels of adiponectin, inflammatory mediators lipid profile, and fasting blood glucose among patients with type II diabetes mellitus. Probiotics Antimicrob. Proteins 9 (2017), 41–47.
6. Giovinazzo, G., Ingrosso, I., Paradiso, A., De Gara, L., Santino, A., Resveratrol biosynthesis: plant metabolic engineering for nutritional improvement of food. Plant Foods Hum Nutr. (Dordrecht, Netherlands) 67 (2012), 191–199.
7. Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148 (2012), 421–433.
8. Gomez, L.S., Zancan, P., Marcondes, M.C., Ramos-Santos, L., Meyer-Fernandes, J.R., Sola-Penna, M., et al. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 95 (2013), 1336–1343.
9. Bellaver, B., Souza, D.G., Souza, D.O., Quincozes-Santos, A., Resveratrol increases antioxidant defenses and decreases proinflammatory cytokines in hippocampal astrocyte cultures from newborn: adult and aged Wistar rats. Toxicology In Vitro: Int. J. Publ. Assoc. BIBRA 28 (2014), 479–484.
10. Fan, E., Zhang, L., Jiang, S., Bai, Y., Beneficial effects of resveratrol on atherosclerosis. J. Med. Food 11 (2008), 610–614.
11. Riccioni, G., Gammone, M.A., Tettamanti, G., Bergante, S., Pluchinotta, F.R., D'Orazio, N., Resveratrol and anti-atherogenic effects. Int. J. Food Sci. Nutr. 66 (2015), 603–610.
12. Kang, S.S., Cuendet, M., Endringer, D.C., Croy, V.L., Pezzuto, J.M., Lipton, M.A., Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1: COX-2 and NF-kappaB. Bioorg. Med. Chem. 17 (2009), 1044–1054.
13. Spanier, G., Xu, H., Xia, N., Tobias, S., Deng, S., Wojnowski, L., et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1): glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J. Physiol. Pharmacol.: Off. J. Pol. Physiol. Soc. 60 (2009), 111–116.
14. Zhang, H., Zhang, J., Ungvari, Z., Zhang, C., Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arteriosclerosis Thrombosis Vasc. Biol. 29 (2009), 1164–1171.
15. Shen, M.Y., Hsiao, G., Liu, C.L., Fong, T.H., Lin, K.H., Chou, D.S., et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol. 139 (2007), 475–485.
16. Miura, D., Miura, Y., Yagasaki, K., Hypolipidemic action of dietary resveratrol a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 73 (2003), 1393–1400.
17. Zhu, L., Luo, X., Jin, Z., Effect of resveratrol on serum and liver lipid profile and antioxidant activity in hyperlipidemia rats. Asian Austral. J. Anim. 21 (2008), 890–895.
18. Chekalina, N.I., Kazakov, Y.M., Mamontova, T.V., Vesnina, L.E., Kaidashev, I.P., Resveratrol more effectively than quercetin reduces endothelium degeneration and level of necrosis factor alpha in patients with coronary artery disease. Wiadomosci. Lekarskie (Warsaw, Poland: 1960) 69 (2016), 475–479.
19. Polycarpou, E., Meira, L.B., Carrington, S., Tyrrell, E., Modjtahedi, H., Carew, M.A., Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors cyclin D1 depletion, and G1 cell cycle arrest. Mol. Nutr. Food Res. 57 (2013), 1708–1717.
20. Lancon, A., Delmas, D., Osman, H., Thenot, J.P., Jannin, B., Latruffe, N., Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem. Biophys. Res. Commun. 316 (2004), 1132–1137.
21. Yu, C., Shin, Y.G., Chow, A., Li, Y., Kosmeder, J.W., Lee, Y.S., et al. Human rat, and mouse metabolism of resveratrol. Pharm. Res. 19 (2002), 1907–1914.
22. Kapetanovic, I.M., Muzzio, M., Huang, Z., Thompson, T.N., McCormick, D.L., Pharmacokinetics oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 68 (2011), 593–601.
23. Voloshyna, I., Hai, O., Littlefield, M.J., Carsons, S., Reiss, A.B., Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine. Eur. J. Pharmacol. 698 (2013), 299–309.
24. Bhatt, J.K., Thomas, S., Nanjan, M.J., Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. (New York, NY) 32 (2012), 537–541.
25. Bo, S., Ciccone, G., Castiglione, A., Gambino, R., De Michieli, F., Villois, P., et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem. 20 (2013), 1323–1331.
26. Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Digestive Liver Dis.: Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 47 (2015), 226–232.
27. Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50 (2012), 179–187.
28. Kreuzfeldt, M., Hamilton-Dutoit, S., Kjaer Poulsen, M., Stodkilde-Jorgensen, H., Moller, H.J., Jessen, N., et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 51 (2016), 456–464.
29. Apostolidou, C., Adamopoulos, K., Iliadis, S., Kourtidou-Papadeli, C., Alterations of antioxidant status in asymptomatic hypercholesterolemic individuals after resveratrol intake. Int. J. Food Sci. Nutr. 67 (2015), 541–552.
30. Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol. Res. 111 (2016), 896–905.
31. Faghihzadeh, F., Adibi, P., Hekmatdoost, A., The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br. J. Nutr. 114 (2015), 796–803.
32. van der Made, S.M., Plat, J., Mensink, R.P., Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One, 10, 2015, e0118393.
33. Zare Javid, A., Hormoznejad, R., Yousefimanesh, H.A., Zakerkish, M., Haghighi-Zadeh, M.H., Dehghan, P., et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytother. Res.: PTR 31 (2017), 108–114.
34. Fujitaka, K., Otani, H., Jo, F., Jo, H., Nomura, E., Iwasaki, M., et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. (New York, NY) 11 (2011), 842–847.
35. Sahebkar, A., Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 71 (2013), 822–835.
36. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
37. Egger, M., Davey-Smith, G., Altman, D., Systematic Reviews in Health Care: Meta-Analysis in Context. Second edition, 2008, Sons JW.
38. Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ (Clin. Res. Ed.) 327 (2003), 557–560.
39. Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 5, 2005, 13.
40. Arzola-Paniagua, M.A., Garcia-Salgado Lopez, E.R., Calvo-Vargas, C.G., Guevara-Cruz, M., Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: a randomized controlled trial. Obesity (Silver Spring, Md) 24 (2016), 1454–1463.
41. Banaszewska, B., Wrotynska-Barczynska, J., Spaczynski, R.Z., Pawelczyk, L., Duleba, A.J., Effects of resveratrol on polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 101 (2016), 4322–4328.
42. Gliemann, L., Schmidt, J.F., Olesen, J., Bienso, R.S., Peronard, S.L., Grandjean, S.U., et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J. Physiol. 591 (2013), 5047–5059.
43. Macedo, R.C., Vieira, A., Marin, D.P., Otton, R., Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test–a placebo-controlled, double blind study. Chem. Biol. Interact. 227 (2015), 89–95.
44. Mendez-del Villar, M., Gonzalez-Ortiz, M., Martinez-Abundis, E., Perez-Rubio, K.G., Lizarraga-Valdez, R., Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 12 (2014), 497–501.
45. Militaru, C., Donoiu, I., Craciun, A., Scorei, I.D., Bulearca, A.M., Scorei, R.I., Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutr. (Burbank, Los Angeles County, Calif.) 29 (2013), 178–183.
46. Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., Radko, Y., Christensen, L.P., Stodkilde-Jorgensen, H., et al. High-dose resveratrol supplementation in obese men: an investigator-initiated randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62 (2013), 1186–1195.
47. Timmers, S., Konings, E., Bilet, L., Houtkooper, R.H., van de Weijer, T., Goossens, G.H., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14 (2011), 612–622.
48. Voduc, N., la Porte, C., Tessier, C., Mallick, R., Cameron, D.W., Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study. Appl. Physiol. Nutr. Metab.=Physiologie appliquee, nutrition et metabolisme 39 (2014), 1183–1187.
49. Zortea, K., Franco, V.C., Francesconi, L.P., Cereser, K.M., Lobato, M.I., Belmonte-de-Abreu, P.S., Resveratrol supplementation in schizophrenia patients: a randomized clinical trial evaluating serum glucose and cardiovascular risk factors. Nutrients, 8, 2016, 73.
50. Heeboll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjaer Poulsen, M., Stodkilde-Jorgensen, H., Moller, H.J., et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 51 (2016), 456–464.
51. Mansur, A.P., Roggerio, A., Goes, M.F.S., Avakian, S.D., Leal, D.P., Maranhao, R.C., et al. Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: a randomized trial. Int. J. Cardiol. 227 (2017), 788–794.
52. Frye, R.A., Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 273 (2000), 793–798.
53. Stunkel, W., Campbell, R.M., Sirtuin 1 (SIRT1): the misunderstood HDAC. J. Biomol. Screen. 16 (2011), 1153–1169.
54. Lasa, A., Schweiger, M., Kotzbeck, P., Churruca, I., Simon, E., Zechner, R., et al. Resveratrol regulates lipolysis via adipose triglyceride lipase. J. Nutr. Biochem. 23 (2012), 379–384.
55. Zamora-Ros, R., Urpi-Sarda, M., Lamuela-Raventos, R.M., Martinez-Gonzalez, M.A., Salas-Salvado, J., Aros, F., et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol. Res. 65 (2012), 615–620.
56. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Garcia-Almagro, F.J., Aviles-Plaza, F., Parra, S., et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 56 (2012), 810–821.
57. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M.J., Garcia-Almagro, F.J., Ruiz-Ros, J.A., et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110 (2012), 356–363.
58. Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C., Caporaso, N., Vescovi, P.P., et al. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 49 (2005), 495–504.
59. Goldberg, D.M., Yan, J., Soleas, G.J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36 (2003), 79–87.
60. Martius, G., Alwahsh, S.M., Rave-Frank, M., Hess, C.F., Christiansen, H., Ramadori, G., et al. Hepatic fat accumulation and regulation of FAT/CD36: an effect of hepatic irradiation. Int. J. Clin. Exp. Pathol. 7 (2014), 5379–5392.
61. Hassan, S., Milman, U., Feld, J., Eder, L., Lavi, I., Cohen, S., et al. Effects of anti-TNF-alpha treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis. Res. Ther., 18, 2016, 261.
62. Palacz-Wrobel, M., Borkowska, P., Paul-Samojedny, M., Kowalczyk, M., Fila-Danilow, A., Suchanek-Raif, R., et al. Effect of apigenin, kaempferol and resveratrol on the gene expression and protein secretion of tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10) in RAW-264.7 macrophages. Biomed. Pharmacother. = Biomedecine & Pharmacotherapie 93 (2017), 1205–1212.
63. Zahedi, H.S., Jazayeri, S., Ghiasvand, R., Djalali, M., Eshraghian, M.R., Effects of polygonum cuspidatum containing resveratrol on inflammation in male professional basketball players. Int. J. Preventive Med. 4 (2013), 1–4.
64. Huang, H., Chen, G., Liao, D., Zhu, Y., Pu, R., Xue, X., The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes. Rev.: Off. J. Int. Assoc. Study Obes. 17:12 (2016), 1329–1340.
65. Zhu, X., Wu, C., Qiu, S., Yuan, X., Li, L., Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr. Metab., 14, 2017, 60.
66. Parks, E.J., Krauss, R.M., Christiansen, M.P., Neese, R.A., Hellerstein, M.K., Effects of a low-fat high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J. Clin. Invest. 104 (1999), 1087–1096.